Backstrom Jay T.
- SEC CIK
- 0001796398
No open-market purchases or sales filed in the past year.
Current role at each company
- AGIO Agios Pharmaceuticals, Inc.Directoras of Jul 10, 2026
- LVTX LAVA Therapeutics NVDirectoras of Nov 17, 2025
- SRRK Scholar Rock Holding CorpCHIEF EXECUTIVE OFFICERas of Mar 12, 2025
- IRON Disc Medicine, Inc.Directoras of Jan 3, 2023
- XLRN Acceleron Pharma IncEVP, Research and Developmentas of Nov 22, 2021
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Backstrom Jay T. as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
SRRK Scholar Rock Holding Corp
CHIEF EXECUTIVE OFFICER3 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 20, 2025 (view filing) | Feb 18 | 2 days | Backstrom Jay T.CHIEF EXECUTIVE OFFICER | SSale | −18.4K | $36.83 | −$676.6K | −5.6%312.0K after | |
| Jan 21, 2025 (view filing) | Jan 16 | 5 days | Backstrom Jay T.CHIEF EXECUTIVE OFFICER | SSale | −22.3K | $44.20 | −$986.0K | −6.3%330.4K after | |
| Feb 20, 2024 (view filing) | Feb 16 | 4 days | Backstrom Jay T.CHIEF EXECUTIVE OFFICER | SSale | −11.6K | $15.74 | −$182.8K | −3.2%352.7K after |